secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001213900-25-100821
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OSTX shareholders approve 200M share increase, Ayala issuance, and plan amendment at annual meeting
--------------------------------------------------------------------------------

- Charter amendment to increase authorized shares from 50M to 150M approved with 12.6M For, 228K Against, 16.3K Abstain.
- Ayala Issuance (shares/warrants equal to ≥20% of outstanding common stock) approved with 12.7M For, 112.5K Against.
- Plan Amendment increasing shares available for issuance from 4M to 10M and raising individual performance-based cap approved (10.9M For, 1.9M Against).
- All six director nominees elected: Paul Romness, John Ciccio, Avril McKean Dieser, Karim Galzahr, Olivier Jarry, Theodore Search.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025100821/0001213900-25-100821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025100821/ea0261939-8k_ostherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-100821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer